Sources of Information

Bevacizumab


Sources added based on a reconsideration request:


Sources added based on a reconsideration request:


Sources added for symptomatic post-radiation necrosis of the central nervous system:


**Bortezomib**


The following sources were added as a result of a reconsideration request received November 21, 2012:


The following sources were added as a result of a reconsideration request received on April 28, 2016:


**Denosumab (Prolia™, Xgeva™)**

Based on a reconsideration request the following sources have been added:


FDA label for Prolia® (denosumab) revised 05/18/2018.


**Eculizumab (Soliris®)**

Peer Reviewed Literature:


**Filgrastim, Pegfilgrastim, Tbo-filgrastim and biosimilars**

Empire Medicare Services carrier LCD NY [L7515]

The following sources were added as a result of a reconsideration request received on March 28, 2012:


**Hyaluronans Intra-articular Injections**


**Ibandronate Sodium (e.g., Boniva®)**


The following references have been added based on a reconsideration request received April 20, 2012


**Infliximab, Infliximab-dyyb, Infliximab-abda (e.g., Remicade™, Inflectra™, Renflexis)**


Intravenous Immune Globulin (IVIG)

CMS Publication 100-03, Medicare National Coverage Decisions Manual, Chapter 1, Section 250.3


Other Medicare contractor policies:

Empire Medicare Services carrier LCD (New Jersey [L3666], New York [L3097])

Anthem East Health Plans fiscal intermediary LCD New Hampshire/Vermont [L658]

Associated Hospital Services fiscal intermediary LCD Maine/ Massachusetts [L445]

NHIC, Corp. LCD Intravenous Immunoglobulin (IVIG) [L3147]

Wisconsin Physicians Service Insurance Corporation LCD Immune Globulins [L30147]


Based on a reconsideration request, the following sources have been added:


Based on a reconsideration request, the following sources have been added:


**Luteinizing Hormone-Releasing Hormone (LHRH) Analogs**


Drug Facts and Comparisons, St. Louis, 1996.


The following source was added as a result of a reconsideration request received May 10, 2016:


Paclitaxel (e.g., Taxol®/Abraxane™)


**Rituximab (Rituxan®), Rituximab and hyaluronidase human (Rituxan Hycela™) and Rituximab-abbs (Truxima®)**


Based on a reconsideration the following sources have been added:


The following sources were added as a result of a reconsideration request received July 24, 2012:


The following sources were added as a result of a reconsideration request received December 26, 2012:


Cocilo D, Grimaldi S, Paolasso I, et al. Immunosuppressive treatment in refractory chronic inflammatory


Based on a reconsideration request the following sources have been added:


Based on a reconsideration request the following sources have been added:


Based on a reconsideration request the following sources have been added:


**Based on a reconsideration request the following sources have been added:**


**Based on a reconsideration request the following sources have been added:**
